Faster global financial news!
Eli Lilly
-
Eli Lilly to acquire Merida Biosciences for up to $2.88 billion, expanding into autoimmune diseases beyond obesity drugs
Eli Lilly agreed to acquire Merida Biosciences for up to $2.88 billion in cash, a move aimed at diversifying its pipeline into autoimmune diseases. The deal, expected to close in Q4 2026, will help Li
-
Yahoo Finance analysis favors Eli Lilly over AbbVie for 2026 healthcare stock investment
Yahoo Finance analysis suggests Eli Lilly and Co (LLY) is a better healthcare stock buy for 2026 compared to AbbVie Inc (ABBV), citing Eli Lilly's strong growth in metabolic and obesity platforms driv
-
Analysis indicates that Eli Lilly and Company's (LLY) second-quarter revenue increased by 48% year-over-year, with its stock price recently reaching $1280, leading to market attention on the possibility of a stock split.
The article analyzes that Eli Lilly's stock price recently reached $1280 per share, with its last stock split occurring nearly 30 years ago in October 1997. Although stock splits typically do not chan
-
Investor's Business Daily: Eli Lilly (LLY) Stock Nears New Buy Point After Strong QTR Earnings, Selected To IBD 50 Growth Stocks To Watch List
Investor's Business Daily: Eli Lilly (LLY) Stock Nears New Buy Point After Strong QTR Earnings, Selected To IBD 50 Growth Stocks To Watch List
-
Dow Jones stock index futures rose, while SpaceX and AMD shares fell, and Arista and Eli Lilly shares rose, with the S&P 500 index remaining at a high level.
Dow Jones stock index futures rose, while SpaceX and AMD shares fell, and Arista and Eli Lilly shares rose, with the S&P 500 index remaining at a high level.
-
Eli Lilly's stock is seen as ripe for a split after its obesity drug-fueled rally pushed shares consistently above $1,000
Eli Lilly's stock is seen as ripe for a split after its obesity drug-fueled rally pushed shares consistently above $1,000
-
Analysis: Novo Nordisk's New Weight-Loss Drugs Face Efficacy Challenges Against Eli Lilly
A recent analysis indicates that Novo Nordisk's stock has fallen 29% over the past 12 months, as its new weight-loss drug candidates face stiff competition from Eli Lilly. Novo Nordisk's CagriSema, a
-
Eli Lilly to acquire Merida Biosciences for up to $2.88 billion, expanding into autoimmune diseases beyond obesity drugs
Eli Lilly agreed to acquire Merida Biosciences for up to $2.88 billion in cash, a move aimed at diversifying its pipeline into autoimmune diseases. The deal, expected to close in Q4 2026, will help Li
-
Yahoo Finance analysis favors Eli Lilly over AbbVie for 2026 healthcare stock investment
Yahoo Finance analysis suggests Eli Lilly and Co (LLY) is a better healthcare stock buy for 2026 compared to AbbVie Inc (ABBV), citing Eli Lilly's strong growth in metabolic and obesity platforms driv
-
Analysis indicates that Eli Lilly and Company's (LLY) second-quarter revenue increased by 48% year-over-year, with its stock price recently reaching $1280, leading to market attention on the possibility of a stock split.
The article analyzes that Eli Lilly's stock price recently reached $1280 per share, with its last stock split occurring nearly 30 years ago in October 1997. Although stock splits typically do not chan
-
Investor's Business Daily: Eli Lilly (LLY) Stock Nears New Buy Point After Strong QTR Earnings, Selected To IBD 50 Growth Stocks To Watch List
Investor's Business Daily: Eli Lilly (LLY) Stock Nears New Buy Point After Strong QTR Earnings, Selected To IBD 50 Growth Stocks To Watch List
-
Dow Jones stock index futures rose, while SpaceX and AMD shares fell, and Arista and Eli Lilly shares rose, with the S&P 500 index remaining at a high level.
Dow Jones stock index futures rose, while SpaceX and AMD shares fell, and Arista and Eli Lilly shares rose, with the S&P 500 index remaining at a high level.
-
Eli Lilly's stock is seen as ripe for a split after its obesity drug-fueled rally pushed shares consistently above $1,000
Eli Lilly's stock is seen as ripe for a split after its obesity drug-fueled rally pushed shares consistently above $1,000
-
Analysis: Novo Nordisk's New Weight-Loss Drugs Face Efficacy Challenges Against Eli Lilly
A recent analysis indicates that Novo Nordisk's stock has fallen 29% over the past 12 months, as its new weight-loss drug candidates face stiff competition from Eli Lilly. Novo Nordisk's CagriSema, a
- No data
Eli Lilly
24H Trending
-
1
Aethir (ATH) Token Value Analysis: Decentralized Cloud Computing Project Potential and Risk Assessment
-
2
NOAH Coin Analysis: Distinguishing Between Controversial Projects and Active Payment Infrastructure
-
3
RIKEN Coin Value Analysis: Numerous Projects Share the Same Name, What's Its Investment Potential?
-
4
FXBK Coin Analysis: What Is It? Is It Worth Investing In?
-
5
Beginner's Guide to Bitcoin Trading: A Comprehensive Analysis of Security Risks and Prevention Strategies
-
6
Bitcoin rises above $77,000, bucking tech selloff driven by AI safety concerns and rising oil prices
-
7
Taiwan to open second quasi-diplomatic mission in the Philippines, sources say
-
8
Cosco Shipping Heavy Industry Completes China IPO Guidance Registration
-
9
Samsung Display develops world's first 6.9-inch mobile OLED panel with 2K resolution, 165Hz refresh rate, and 30% lower power consumption
-
10
ATPAD (AtomPad) Project Status Analysis: An Inactive Cryptocurrency
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
